Pharmaceuticals

Global Arthritis Monoclonal Antibodies Market Forecast 2026–2035 Highlighting Long-Term Growth Potential

April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Arthritis Monoclonal Antibodies Market At The End Of The 2026–2030 Forecast Period?

The market size for arthritis monoclonal antibodies has demonstrated robust growth in recent years. This market is set to expand from $66.45 billion in 2025 to $71.66 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.8%. Historically, this expansion has been driven by factors such as the increasing prevalence of rheumatoid arthritis, the restricted effectiveness of conventional DMARDs, heightened awareness of biologic therapies, the growth of hospital-based rheumatology care, and rising healthcare expenditure.

The market for arthritis monoclonal antibodies is projected to experience substantial expansion in the coming years. This market is anticipated to reach $98.46 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.3%. Key factors contributing to this growth during the forecast period include the advancement of next-generation monoclonal antibodies, a rise in biosimilar introductions, the expansion of personalized immunotherapy techniques, an increase in the aging demographic afflicted with arthritis, and enhancements in reimbursement policies for biologics. Noteworthy trends expected over the forecast horizon encompass a greater acceptance of biologic therapies for autoimmune arthritis, a growing inclination towards targeted monoclonal antibody treatments, an increase in proactive and intensive treatment methodologies, the proliferation of biosimilars specifically for arthritis monoclonal antibodies, and enhanced patient accessibility via hospitals and specialized clinics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3449&type=smp

Which Market Drivers Are Supporting The Expansion Of The Arthritis Monoclonal Antibodies Market?

The increasing approvals of personalized medicines are anticipated to drive growth in the arthritis monoclonal antibody market moving ahead. Personalized medicines are defined as therapeutic products or treatments specifically designed for individual patients. Their design considers a patient’s genetic, biomarker, phenotypic, or psychosocial traits, which can forecast how an individual will respond to a particular treatment. Monoclonal antibodies (mABs) represent the newest class of drugs aligning with the personalized medicine framework, offering the prospect of enhancing patient outcomes and healthcare efficiency. For example, in February 2024, a report by the Personalized Medicine Coalition, a US-based non-profit advocating for personalized medicine adoption, highlighted the significance of 26 newly approved personalized treatments, 19 expanded indications for existing personalized medicines, and 17 notable new or expanded indications for 12 diagnostic testing products. Consequently, the growing number of approvals for personalized medicines is a key driver for the arthritis monoclonal antibody market.

What Segment Types Make Up The Arthritis Monoclonal Antibodies Market?

The arthritis monoclonal antibodies market covered in this report is segmented –

1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima

2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications

3) By End-Use: Hospitals, Research Institutes, Other End-Users

Which Market Trends Are Creating New Opportunities In The Arthritis Monoclonal Antibodies Market?

Leading companies in the arthritis monoclonal antibody market are introducing new biosimilar versions, such as Hulio, to make treatment more affordable. Hulio is a biosimilar form of Humira, AbbVie’s successful drug for rheumatoid arthritis. For example, in July 2023, Biocon Biologics, an India-based subsidiary of Biocon Limited focused on developing biosimilar therapies, launched Hulio (adalimumab-fkjp), which is a biosimilar counterpart to Humira. This monoclonal antibody, prescribed for conditions like rheumatoid arthritis and psoriatic arthritis, is priced 5% lower than Humira, which currently lists at $6,922 per carton.

Who Are The Key Players Driving Competition In The Arthritis Monoclonal Antibodies Market?

Major companies operating in the arthritis monoclonal antibodies market are Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.

Read the full arthritis monoclonal antibodies market report here:

https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report

How Is The Arthritis Monoclonal Antibodies Market Distributed Across Key Geographic Regions?

North America was the largest region in the arthritis monoclonal antibodies market in 2025. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Arthritis Monoclonal Antibodies Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3449&type=smp

Browse Through More Reports Similar to the Global Arthritis Monoclonal Antibodies Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Microbiome Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Orthobiologics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795